BioSpace News Archive

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, is presenting data on the activity of the company’s tumor-derived immunotherapies in glioblastoma and other solid tumors at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, La.

Orphagen Pharmaceuticals Inc., a biotech company pioneering the screening, discovery, and development of small molecule ligands that modulate orphan or unexplored members of the nuclear receptor family, today announced a late-breaking presentation of new preclinical data for OR-449 at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13 both virtually and in-person in New Orleans.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced two poster presentations on its clinical stage program IO-108, a novel myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4), at the American Association for Cancer Research (AACR) Annual Meeting.

Xencor Presents Data from Multiple Preclinical XmAb ® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced data from the dose escalation phase of the phase 1/2a study with the Company’s Innate Cell Engager (ICE®) AFM24 as monotherapy at the Annual Meeting of the American Association of Cancer Research (AACR).

Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced study findings accepted for presentation at The American Association for Cancer Research (AACR) Annual Meeting taking place in New Orleans, LA, Friday, April 8 – Wednesday, April 13.

Seagen Inc. (Nasdaq: SGEN) today announced data from intravesical instillation of enfortumab vedotin (EV) in a non-muscle invasive bladder cancer (NMIBC) preclinical model in addition to preclinical data from SGN-ALPV and SGN-B7H4V, two of its novel antibody-drug conjugates (ADCs) that utilize the company’s proprietary vedotin drug linker technology.

Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the American Association of Cancer Research’s annual meeting in New Orleans on April 12th, 2022 is now available on both the AACR and Cytovia websites.

The global medical fiber optics market size is predicted to surpass around USD 2.6 billion by 2030 from valued at USD 920.9 million in 2020, growing at a CAGR of 6.02% from 2022 to 2030.

Nitric oxide has witnessed increased demand owing to its rise in use in the medical sector and during the Covid-19 pandemic.